X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (236) 236
hematology (124) 124
platelet glycoprotein gpiib-iiia complex - antagonists & inhibitors (107) 107
male (100) 100
cardiac & cardiovascular systems (92) 92
female (89) 89
platelet aggregation inhibitors - therapeutic use (87) 87
peripheral vascular disease (84) 84
gp iib/iiia (76) 76
abciximab (73) 73
middle aged (69) 69
index medicus (68) 68
gp iib/iiia inhibitors (67) 67
platelets (66) 66
platelet aggregation inhibitors - pharmacology (59) 59
aged (52) 52
percutaneous coronary intervention (51) 51
treatment outcome (50) 50
thrombosis (49) 49
animals (47) 47
platelet aggregation - drug effects (46) 46
acute coronary syndromes (42) 42
unstable angina (42) 42
aggregation (39) 39
antibodies, monoclonal - therapeutic use (38) 38
immunoglobulin fab fragments - therapeutic use (37) 37
blood platelets - drug effects (36) 36
blood platelets - metabolism (35) 35
fibrinogen (35) 35
tirofiban (35) 35
tyrosine - analogs & derivatives (35) 35
acute myocardial-infarction (33) 33
medicine & public health (33) 33
platelet glycoprotein gpiib-iiia complex - metabolism (33) 33
pharmacology & pharmacy (32) 32
platelet (32) 32
platelet aggregation (32) 32
flow cytometry (31) 31
adult (30) 30
eptifibatide (30) 30
aspirin (29) 29
cardiology (29) 29
platelet aggregation inhibitors - administration & dosage (29) 29
angioplasty (28) 28
activation (27) 27
clopidogrel (27) 27
risk factors (27) 27
stents (27) 27
heparin (26) 26
platelet aggregation inhibitors - adverse effects (26) 26
primary angioplasty (26) 26
acute coronary syndrome (25) 25
thrombolysis (25) 25
angioplasty, balloon, coronary (24) 24
myocardial infarction - drug therapy (24) 24
antibodies, monoclonal - pharmacology (22) 22
inhibition (22) 22
monoclonal-antibody (22) 22
myocardial infarction (22) 22
myocardial infarction - therapy (22) 22
platelet activation - drug effects (22) 22
biochemistry & molecular biology (21) 21
fibrinolytic agents - therapeutic use (21) 21
receptor (21) 21
gp iib-iiia (20) 20
integrin (20) 20
myocardial-infarction (20) 20
therapy (20) 20
time factors (20) 20
anticoagulants - therapeutic use (19) 19
antiplatelet agents (19) 19
randomized controlled trials as topic (19) 19
trial (19) 19
von-willebrand-factor (19) 19
blockade (18) 18
blood platelets - physiology (18) 18
drug therapy, combination (18) 18
gp iib (18) 18
gp-iib-iiia (18) 18
immunoglobulin fab fragments - pharmacology (18) 18
platelet activation (18) 18
tyrosine - therapeutic use (18) 18
coronary heart disease (17) 17
dose-response relationship, drug (17) 17
gp iib/iiia antagonists (17) 17
thrombin (17) 17
unfractionated heparin (17) 17
adhesion (16) 16
aged, 80 and over (16) 16
analysis (16) 16
bivalirudin (16) 16
coronary angiography (16) 16
hemorrhage - chemically induced (16) 16
integrins (16) 16
myocardial infarction - mortality (16) 16
pci (16) 16
cardiovascular (15) 15
elevation myocardial-infarction (15) 15
p-selectin (15) 15
platelet count (15) 15
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (421) 421
German (34) 34
French (11) 11
Japanese (7) 7
Polish (4) 4
Chinese (2) 2
Portuguese (2) 2
Russian (2) 2
Spanish (2) 2
Czech (1) 1
Italian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
JACC: Cardiovascular Interventions, ISSN 1936-8798, 2015, Volume 8, Issue 1, pp. 201 - 213
Abstract Objectives The aim of this meta-analysis was to compare the 30-day safety and efficacy of bivalirudin with those of heparin with or without routine... 
Cardiovascular | heparin | meta-analysis | GP IIb/IIIa inhibitor | acute coronary syndrome | bivalirudin | Bivalirudin | Heparin | Acute coronary syndrome | Meta-analysis | CARDIAC & CARDIOVASCULAR SYSTEMS | THROMBOSIS | BARE-METAL STENTS | STRATEGY | RISK | TRIAL | OUTCOMES | INTERVENTION | ELEVATION MYOCARDIAL-INFARCTION | UNFRACTIONATED HEPARIN | PLUS | Recombinant Proteins - therapeutic use | Humans | Acute Coronary Syndrome - mortality | Heparin - therapeutic use | Recombinant Proteins - adverse effects | Heparin - adverse effects | Time Factors | Platelet Glycoprotein GPIIb-IIIa Complex - metabolism | Coronary Thrombosis - prevention & control | Blood Platelets - drug effects | Odds Ratio | Platelet Aggregation Inhibitors - therapeutic use | Myocardial Infarction - etiology | Platelet Aggregation Inhibitors - adverse effects | Risk Factors | Anticoagulants - therapeutic use | Treatment Outcome | Anticoagulants - adverse effects | Chi-Square Distribution | Acute Coronary Syndrome - blood | Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors | Randomized Controlled Trials as Topic | Acute Coronary Syndrome - drug therapy | Blood Platelets - metabolism | Hirudins - adverse effects | Acute Coronary Syndrome - diagnosis | Coronary Thrombosis - etiology | Myocardial Infarction - prevention & control | Peptide Fragments - adverse effects | Peptide Fragments - therapeutic use | Hemorrhage - chemically induced
Journal Article
Blood Coagulation & Fibrinolysis, ISSN 0957-5235, 06/2013, Volume 24, Issue 4, pp. 411 - 418
Glycoprotein IIb-IIIa (Gp IIb-IIIa), a fibrinogen receptor located on platelet surface, is a key point in the pathway leading to platelet aggregation.... 
platelet glycoprotein IIIa | Gp IIb-IIIa inhibitors | platelet polymorphism
Journal Article
Blood Coagulation & Fibrinolysis, ISSN 0957-5235, 2013, Volume 24, Issue 4, pp. 411 - 418
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 06/2004, Volume 43, Issue 12, pp. 2319 - 2325
The purpose of this study was to examine the effects of glycoprotein (GP) IIb/IIIa antagonists (abciximab, eptifibatide, and tirofiban) and other inhibitors on... 
MMPs | GP | EDTA | HT | HEPES Tyrode's buffer | phycoerythrin | FITC | percutaneous coronary intervention | PE | enzyme-linked immunosorbent assay | ethylenediaminetetraacetic acid | PCI | glycoprotein | PerCP | fluorescein isothiocyanate | matrix metalloproteinases | ELISA | ACTIVATION | CYTOKINES | CARDIAC & CARDIOVASCULAR SYSTEMS | STIMULATION | INHIBITION | ENDOTHELIAL-CELLS | DISEASE | ACUTE CORONARY SYNDROMES | LIGAND CD40L | ANTAGONISTS | EXPRESSION | Tumor Necrosis Factor-alpha - metabolism | Chelating Agents - administration & dosage | Humans | Cytochalasin D - administration & dosage | Dose-Response Relationship, Drug | Thrombasthenia - blood | CD40 Ligand - metabolism | Platelet Glycoprotein GPIIb-IIIa Complex - administration & dosage | Matrix Metalloproteinases - drug effects | Platelet Aggregation Inhibitors - administration & dosage | Protease Inhibitors - administration & dosage | Destrin | Blood Platelets - drug effects | Nucleic Acid Synthesis Inhibitors - administration & dosage | Solubility | Actin Depolymerizing Factors | Edetic Acid - administration & dosage | Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors | Dipeptides - administration & dosage | CD40 Ligand - drug effects | Tumor Necrosis Factor-alpha - drug effects | Microfilament Proteins - administration & dosage | Blood Platelets - metabolism | Platelet Activation - drug effects | Matrix Metalloproteinases - metabolism | Transluminal angioplasty | Chlorophyll | Actin | Fluorescein | Polymerization | Muscle proteins | Enzyme-linked immunosorbent assay | Cardiovascular agents | Enzymes | Flow cytometry | Hypotheses | Peptides | Blood platelets | Atherosclerosis | Cytoskeleton | Ligands | Muscular system | Thrombosis | Binding sites
Journal Article
Cardiovascular Revascularization Medicine, ISSN 1553-8389, 12/2018, Volume 19, Issue 8, pp. 956 - 959
Bioresorbable Vascular Scaffolds (BVS) have the potential for adaptive vessel remodeling, restoration of vasomotion, and late luminal enlargement, thus... 
GP IIb/IIIa inhibitor (GPI) | Scaffold thrombosis (ScT) | Bioresorbable Vascular Scaffold (BVS) | Usage | Thrombosis | Cardiac patients | Blood clot
Journal Article
Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 12/2011, Volume 9, Issue 12, pp. 2361 - 2370
Background: Even although time to treatment has been shown to be a determinant of mortality in primary angioplasty, the potential benefits are still unclear... 
STEMI | primary angioplasty | facilitation | meta‐analysis | Gp IIb‐IIIa inhibitors
Journal Article
Journal Article